BSTG - Biostage, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD

Biostage, Inc.

84 October Hill Road
Suite 11
Holliston, MA 01746
United States

Full Time Employees14

Key Executives

NameTitlePayExercisedYear Born
Mr. James J. McGorryCEO & Director420.6kN/A1956
Dr. William L. Fodor Ph.D.Chief Scientific Officer287.34kN/A1959
Yu HongPresN/AN/A1973
Ms. Ginger A. Abraham-FreelDirector of Quality & OperationsN/AN/AN/A
Mr. Peter M. ChakoutisPrincipal Accounting OfficerN/AN/A1966
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Biostage, Inc., a biotechnology company, engages in developing bioengineered organ implants based on its Cellframe technology. The company's Cellframe technology comprises a biocompatible scaffold that is seeded with the recipient's own stem cells. It is developing its Cellframe technology to treat life-threatening conditions of the esophagus, bronchus, or trachea. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2007 and is headquartered in Holliston, Massachusetts.

Corporate Governance

Biostage, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.